Last 12 months
Inside the activity.
9 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 4 | 0 |
| Jun 2026 | 1 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 1 | 1 |
| Sep 2026 | 1 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2023 Filed May 6, 2023 00:16 UTC |
Aryeh JasonDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 11,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037023 · ownership.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 11,246 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 6, 2023 00:14 UTC |
Fain Eric SDirector
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 4,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037021 · ownership.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 4,796 Underlying: Common Stock · 4,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 6, 2023 00:14 UTC |
Fain Eric SDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 4,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037021 · ownership.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 26,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC |
Hochman David PDirector · See Remarks
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · derivative · entry 6 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the NSH 2008 Family Trust Disclosed balance after: 683 Underlying: Common Stock · 683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC |
Hochman David PDirector · See Remarks
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 11,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · derivative · entry 5 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 11,160 Underlying: Common Stock · 11,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC |
Hochman David PDirector · See Remarks
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 29,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · derivative · entry 4 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,551 Underlying: Common Stock · 29,551 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC |
Hochman David PDirector · See Remarks
|
Exercise / conversionCommon Stock | 683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · nonDerivative · entry 3 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the NSH 2008 Family Trust Disclosed balance after: 3,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC |
Hochman David PDirector · See Remarks
|
Exercise / conversionCommon Stock | 11,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By the DPH 2008 Trust Disclosed balance after: 62,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:39 UTC |
Hochman David PDirector · See Remarks
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 29,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-037001 · ownership.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 29,551 shares of Common Stock, 11,160 shares of Common Stock and 683 shares of Common Stock were issued to David P. Hochman, the DPH 2008 Trust and the NSH 2008 Family Trust, respectively, on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:35 UTC |
Sherman DarrenDirector · See Remarks
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 14,959 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-036999 · ownership.xml · derivative · entry 2 Sherman Darren · CIK 0001723524 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,959 Underlying: Common Stock · 14,959 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 14,959 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 14,959 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 14,959 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 14,959 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 14,959 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 5, 2023 23:35 UTC |
Sherman DarrenDirector · See Remarks
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 14,959 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-036999 · ownership.xml · nonDerivative · entry 1 Sherman Darren · CIK 0001723524 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 14,959 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 14,959 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 55,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 8 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures Synecor, LP Disclosed balance after: 55,783 Underlying: Common Stock · 55,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 228,073 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 7 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II, LP Disclosed balance after: 228,073 Underlying: Common Stock · 228,073 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 43,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 6 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II NY, LP Disclosed balance after: 43,761 Underlying: Common Stock · 43,761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionRight to Receive Earnout Shares · Derivative | 758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · derivative · entry 5 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 758 Underlying: Common Stock · 758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 55,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 4 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures Synecor, LP Disclosed balance after: 312,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 228,073 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 3 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II, LP Disclosed balance after: 1,277,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 43,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 2 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Ascent Biomedical Ventures II NY, LP Disclosed balance after: 245,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F3 · ownership.nature: The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein. Read SEC document |
| April 12, 2023 Filed May 8, 2023 11:47 UTC |
Smith Geoffrey WadeDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock") | 758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-056865 · tm2314913-1_4seq1.xml · nonDerivative · entry 1 Smith Geoffrey Wade · CIK 0001418239 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:53 UTC |
Medtronic plc10% owner
|
PurchaseCommon Stock | 6,835 | $9.28 | $63,435.64 |
DisclosureSEC source: 0001062993-23-001819 · form4.xml · nonDerivative · entry 1 Medtronic plc · CIK 0001613103 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Covidien Group S.a.r.l. Disclosed balance after: 4,999,423 Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:28 UTC |
ROSE ERIC A MDDirector
|
GrantWarrant (Right to Buy) · Derivative | 2,325 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001213900-23-006181 · ownership.xml · derivative · entry 5 ROSE ERIC A MD · CIK 0001139301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,325 Underlying: Common Stock · 2,325 shares Expires 2023-05-31 F7 · price: Received in the Business Combination in exchange for warrants to purchase 5,000 shares of Legacy Orchestra Common Stock for $0.50 per share. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:28 UTC |
ROSE ERIC A MDDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 3,488 | Not disclosed Strike: $4.06 | Not disclosed |
DisclosureSEC source: 0001213900-23-006181 · ownership.xml · derivative · entry 4 ROSE ERIC A MD · CIK 0001139301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,488 Underlying: Common Stock · 3,488 shares Expires 2032-04-11 F6 · price: Received in the Business Combination in exchange for an incentive stock option to acquire 7,500 shares of Legacy Orchestra Common Stock for $1.89 per share. F5 · derivative.exercise_date: The incentive stock options vests annually in equal installments over a two-year period starting with the first anniversary of the grant date, subject to the Reporting Person's continuous service through such date. The grant date is April 12, 2022. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:28 UTC |
ROSE ERIC A MDDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 23,250 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-006181 · ownership.xml · derivative · entry 3 ROSE ERIC A MD · CIK 0001139301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-25 F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F3 · derivative.exercise_date: The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis, starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:28 UTC |
ROSE ERIC A MDDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 6,975 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006181 · ownership.xml · derivative · entry 2 ROSE ERIC A MD · CIK 0001139301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2029-08-06 F2 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:28 UTC |
ROSE ERIC A MDDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 18,600 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006181 · ownership.xml · derivative · entry 1 ROSE ERIC A MD · CIK 0001139301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2028-11-16 F1 · price: These securities were received on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for a nonstatutory stock option ("NSO") to acquire 40,000 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock") for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:36 UTC |
Mika YuvalDirector · See Remarks
|
GrantIncentive Stock Option (Right to Buy) · Derivative | 46,500 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006198 · ownership.xml · derivative · entry 4 Mika Yuval · CIK 0001949285 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 46,500 shares Expires 2028-08-07 F6 · price: Received in the Business Combination in exchange for an incentive stock option to acquire 100,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:36 UTC |
Mika YuvalDirector · See Remarks
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 234,242 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-006198 · ownership.xml · derivative · entry 3 Mika Yuval · CIK 0001949285 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,242 Underlying: Common Stock · 234,242 shares Expires 2032-08-25 F5 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 503,746 shares of Legacy Orchestra Common Stock for $4.65 per share. F4 · derivative.exercise_date: The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:36 UTC |
Mika YuvalDirector · See Remarks
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 69,870 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006198 · ownership.xml · derivative · entry 2 Mika Yuval · CIK 0001949285 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,870 Underlying: Common Stock · 69,870 shares Expires 2028-08-07 F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 150,259 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:36 UTC |
Mika YuvalDirector · See Remarks
|
GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 40,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-006198 · ownership.xml · nonDerivative · entry 1 Mika Yuval · CIK 0001949285 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,720 F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. F2 · price: Received in the Business Combination in exchange for 87,571 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:35 UTC |
Kaswan MichaelChief Financial Officer
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 192,566 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-006196 · ownership.xml · derivative · entry 2 Kaswan Michael · CIK 0001324483 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,566 Underlying: Common Stock · 192,566 shares Expires 2032-08-25 F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 414,120 shares of Legacy Orchestra Common Stock for $4.65 per share. F3 · derivative.exercise_date: The nonstatutory stock options have vested and will vest in equal installments over a three-year period on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:35 UTC |
Kaswan MichaelChief Financial Officer
|
GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 133,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-006196 · ownership.xml · nonDerivative · entry 1 Kaswan Michael · CIK 0001324483 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,545 F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. F2 · price: Received in the Business Combination in exchange for 287,194 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:34 UTC |
Connealy Pamela AnnDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 23,250 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-006193 · ownership.xml · derivative · entry 3 Yanchik Connealy Pamela · CIK 0001796310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-25 F6 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F5 · derivative.exercise_date: The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such date. The grant date is August 18, 2022. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:34 UTC |
Connealy Pamela AnnDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 18,600 | Not disclosed Strike: $7.66 | Not disclosed |
DisclosureSEC source: 0001213900-23-006193 · ownership.xml · derivative · entry 2 Yanchik Connealy Pamela · CIK 0001796310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2030-06-29 F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 40,000 shares of Legacy Orchestra Common Stock for $3.56 per share. F3 · derivative.exercise_date: The nonstatutory stock options ("NSOs") have vested and will vest in equal installments over a three-year period on a quarterly basis, starting with the last day of the last month of the first quarter after the grant date, subject to the Reporting Person's continuous service through such date. The grant date is June 30, 2020. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:34 UTC |
Connealy Pamela AnnDirector
|
GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 3,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-006193 · ownership.xml · nonDerivative · entry 1 Yanchik Connealy Pamela · CIK 0001796310 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,488 F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. F2 · price: Received in the Business Combination in exchange for 7,500 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:32 UTC |
Aiello JoshuaPrincipal Accounting Officer
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 18,228 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-006191 · ownership.xml · derivative · entry 5 Aiello Joshua · CIK 0001960418 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,228 Underlying: Common Stock · 18,228 shares Expires 2032-08-25 F9 · price: Received in the Business Combination in exchange for an incentive stock option to acquire 39,200 shares of Legacy Orchestra Common Stock for $4.65 per share. F8 · derivative.exercise_date: The incentive stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the day of the month of each quarter that is the same day of the month as the grant date, starting with the corresponding date in the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:32 UTC |
Aiello JoshuaPrincipal Accounting Officer
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 4,650 | Not disclosed Strike: $4.06 | Not disclosed |
DisclosureSEC source: 0001213900-23-006191 · ownership.xml · derivative · entry 4 Aiello Joshua · CIK 0001960418 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650 Underlying: Common Stock · 4,650 shares Expires 2032-04-11 F7 · price: Received in the Business Combination in exchange for an incentive stock option to acquire 10,000 shares of Legacy Orchestra Common Stock for $1.89 per share. F6 · derivative.exercise_date: The incentive stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis, on the day of the month of each quarter that is the same day of the month as the grant date, starting with the corresponding date in the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is April 12, 2022. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:32 UTC |
Aiello JoshuaPrincipal Accounting Officer
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 4,185 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001213900-23-006191 · ownership.xml · derivative · entry 3 Aiello Joshua · CIK 0001960418 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2031-08-04 F5 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 9,000 shares of Legacy Orchestra Common Stock for $2.21 per share. F4 · derivative.exercise_date: The NSOs have vested and will vest in equal installments over a three-year period on a monthly basis, on the day of the month of each month that is the same day of the month as the grant date, starting with the first month after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 5, 2021. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:32 UTC |
Aiello JoshuaPrincipal Accounting Officer
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 6,975 | Not disclosed Strike: $7.66 | Not disclosed |
DisclosureSEC source: 0001213900-23-006191 · ownership.xml · derivative · entry 2 Aiello Joshua · CIK 0001960418 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2030-10-13 F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $3.56 per share. F2 · derivative.exercise_date: The nonstatutory stock options ("NSOs") have vested and will vest in equal installments over a three-year period on a monthly basis, on the day of the month of each month that is the same day of the month as the grant date, starting with the first month after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is October 14, 2020. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:32 UTC |
Aiello JoshuaPrincipal Accounting Officer
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 6,975 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006191 · ownership.xml · derivative · entry 1 Aiello Joshua · CIK 0001960418 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2029-08-06 F1 · price: These securities were received on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for a nonstatutory stock option to acquire 15,000 shares of common stock of Legacy Orchestra Legacy Orchestra ("Legacy Orchestra Common Stock") for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:31 UTC |
Aryeh JasonDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 23,250 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-006188 · ownership.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-25 F6 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F5 · derivative.exercise_date: The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis on the day of the month of each quarter that is the same day of the month as the grant date, starting with the corresponding date in the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:31 UTC |
Aryeh JasonDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 6,975 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006188 · ownership.xml · derivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2029-08-06 F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:31 UTC |
Aryeh JasonDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 18,600 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006188 · ownership.xml · derivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2028-11-16 F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 40,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:31 UTC |
Aryeh JasonDirector
|
GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 51,738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-006188 · ownership.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,738 F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. F2 · price: Received in the Business Combination in exchange for 111,263 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:29 UTC |
Fain Eric SDirector
|
GrantWarrant (Right to Buy) · Derivative | 2,906 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 5 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 2,906 Underlying: Common Stock · 2,906 shares Expires 2023-05-31 F7 · price: Received in the Business Combination in exchange for warrants to purchase 6,250 shares of Legacy Orchestra Common Stock for $0.50 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:29 UTC |
Fain Eric SDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 23,250 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 4 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-25 F6 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F5 · derivative.exercise_date: The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis, starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:29 UTC |
Fain Eric SDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 6,975 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 3 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2029-08-06 F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:29 UTC |
Fain Eric SDirector
|
GrantNonstatutory Stock Option (Right to Buy) · Derivative | 18,600 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2028-11-16 F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 40,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:29 UTC |
Fain Eric SDirector
|
GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 22,065 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-006184 · ownership.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 22,065 F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. F2 · price: Received in the Business Combination in exchange for 47,450 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:26 UTC |
Hochman David PDirector · See Remarks
|
GrantWarrant (Right to Buy) · Derivative | 410 | Not disclosed Strike: $21.51 | Not disclosed |
DisclosureSEC source: 0001213900-23-006179 · ownership.xml · derivative · entry 12 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By the NSH 2008 Family Trust Disclosed balance after: 410 Underlying: Common Stock · 410 shares Expires 2023-05-31 F18 · price: Received in the Business Combination in exchange for warrants to purchase 881 shares of Legacy Orchestra Common Stock for $10.00 per share. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:26 UTC |
Hochman David PDirector · See Remarks
|
GrantWarrant (Right to Buy) · Derivative | 422 | Not disclosed Strike: $21.51 | Not disclosed |
DisclosureSEC source: 0001213900-23-006179 · ownership.xml · derivative · entry 11 Hochman David P · CIK 0001292834 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422 Underlying: Common Stock · 422 shares Expires 2023-05-31 F17 · price: Received in the Business Combination in exchange for warrants to purchase 907 shares of Legacy Orchestra Common Stock for $10.00 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.